SAB Biotherapeutics, Inc. SABS

3.29 (0.06) (1.79%) as of 25 Sep
Market cap
$304.8M
P/E
0.0×
Dec '17 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 —
P/S ratio
— 0.00 3.51 1.18 17.26 21.57 —
P/FCF ratio
— 0.00 0.00 0.00 0.00 0.00 —
P/Operating CF
— (150,140.83) (43.77) (18.19) (2.87) (3.68) —
P/B ratio
— 93,838.02 5.54 0.91 0.67 1.35 —
Price to Tangible BV
— 93,838.02 5.54 0.91 0.67 1.35 —
EV/Sales
— 0.00 2.92 0.73 (6.47) 10.83 —
EV/EBITDA
— 0.00 0.00 0.00 0.42 0.00 —
EV/Operating CF
— 0.00 89.45 (0.74) 0.58 (0.51) —
EV/FCF
— 0.00 (19.84) (0.68) 0.57 (0.51) —
Quick Ratio
— 3.00 1.80 1.37 5.23 2.61 9.13
Current Ratio
— 3.11 1.90 1.47 5.45 2.98 9.46
Net Debt/EBITDA
— (0.40) 3.05 0.42 1.55 0.46 2.03
Debt/Assets
0.00% 7.24% 4.64% 8.19% 4.07% 7.41% 1.81%
Debt/Equity
— 0.11 0.10 0.13 0.06 0.13 0.02
Asset Turnover
— 1.95 0.88 0.36 0.03 0.02 0.00
Operating CF/Net income
— 0.50 (0.12) 1.25 0.60 1.01 (10.51)
Capex/Depreciation
— (23.21) (6.62) (0.63) (0.04) (0.07) (0.31)
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 51.88% (44.21%) (53.85%) (95.51%) (81.92%) 4.80%
ROA
— 71.17% (24.91%) (28.39%) (62.58%) (53.23%) 3.93%
ROIC
— 42.13% (302.49%) (89.55%) (573.17%) (316.08%) (52.73%)
Return on Tangible Assets
— 52.61% (35.68%) (61.74%) (62.21%) (109.38%) 4.11%
Average Days of Receivables
— 135.92 48.03 84.85 0.00 15.18 0.00
Research and Development Expense of Revenue
— 50.52% 93.93% 152.44% 737.61% 2,287.64% 0.00%
Selling, General and Administrative Expense of Revenue
— 12.26% 28.07% 68.54% 1,062.94% 1,057.27% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 2.35% 3.80% 11.19% 108.25% 222.46% 0.00%
Graham Net Nets
— 0.00 0.04 0.08 0.83 0.16 —
Graham Number
— 0.00 0.00 0.00 0.00 0.00 —
Earnings Yield
— 0.00% (8.03%) (65.84%) (110.63%) (97.10%) —
Free Cash Flow Yield
— 0.00% (4.19%) (90.31%) (65.39%) (98.65%) —
Revenue per Share
— 21.75 22.27 5.49 0.41 0.14 0.00
Operating CF per Share
— 3.94 0.73 (5.39) (4.55) (3.70) (2.32)
Capex per Share
— (5.01) (4.00) (0.48) (0.03) (0.04) (0.05)
Free Cash Flow per Share
— (1.07) (3.28) (5.87) (4.58) (3.74) (2.37)
Cash per Share
— 4.97 14.46 3.46 10.24 2.24 5.00
Shareholders Equity per Share
— 15.36 14.10 7.14 10.38 2.80 7.84
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 15.36 14.10 7.14 10.38 2.80 7.84
Free Cash Flow
— (2.72) (8.96) (25.55) (25.27) (34.63) (45.71)
Working Capital
— 23.39 23.74 7.10 48.09 15.81 90.37
Capital Expenditures
— (12.72) (10.94) (2.09) (0.15) (0.34) (0.93)
Net Current Asset Value
— 16.92 7.60 2.25 32.27 5.57 79.74
EV/EBIT
— 0.00 0.00 0.00 0.38 0.00 —
Capex to Sales
— 0.23 0.18 0.09 0.07 0.26 0.00
Net Profit Margin
— 36.42% (28.16%) (78.40%) (1,884.49%) (2,579.05%) 0.00%
Price to Operating Income
— 0.00 0.00 0.00 0.00 0.00 —
Other line items
Depreciation/Fixed assets
— 0.04 0.07 0.14 0.19 0.30 0.22
Cash ROIC
— (8.69%) (27.28%) (92.91%) (38.25%) (99.31%) (23.12%)
Accounts Receivable Turnover
— 3.87 4.26 3.52 0.00 0.47 0.00
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 0.00 0.00 — — —
Average Receivables
— 14.29 14.29 6.78 — 2.81 0.50
Average Payables
— 5.92 5.92 4.07 2.31 1.32 2.42
Average Assets
— 28.27 68.84 66.02 67.42 64.07 108.50
Average Common Equity
— 38.78 38.78 34.80 44.18 41.63 88.73

Fold the line items

Columns are period end dates